<DOC>
	<DOCNO>NCT01519271</DOCNO>
	<brief_summary>Mild cognitive impairment , include difficulty solve problem , planning , attention , recall information , significant problem individual Parkinson 's disease . Even mild cognitive difficulty lead bad functioning , quality life , depression , difficulty caregiver . Thus , ideally treatment stage would improve cognitive symptom problem associate symptom . Despite fact mild cognitive impairment serious problem Parkinson 's disease patient little known best treat . This study 24-week clinical trial see Food Drug Administration ( FDA ) -approved drug , Exelon ( rivastigmine ) Patch , useful treat mild cognitive impairment patient Parkinson 's disease . Currently , Exelon ( rivastigmine ) Patch FDA-approved treatment mild moderate dementia Alzheimer Parkinson 's disease patient .</brief_summary>
	<brief_title>Mild Cognitive Impairment Parkinson 's Disease</brief_title>
	<detailed_description>This study 2 phase . Each phase last 10 week 4-week break 2 phase . Thus , enrol study total 24 week . Over course 24-week period schedule see in-person 6 time check-in telephone 4 time , 2 time phase . Phase I Screening ( may day baseline visit ) - Research personnel determine eligible participate study . Visit 1 - Baseline Visit , Start Study Medication Phone Call 1 - Check see feel start study medication Visit 2 - 4 Weeks Baseline , Increase Study Medication tolerate Phone Call 2 - Check see feel increase study medication Visit 3/ Phase I Termination Visit - 10 Weeks Baseline ( Phase I Termination Visit ) 4 Week Break ( study medication ) Phase II Visit 4/ Phase II Baseline - 14 Weeks Baseline , Start Study Medication Phone Call 3 - Check see feel start study medication Visit 5 - 18 Weeks Baseline , Increase Study Medication Phone Call 4 - Check see feel increase study medication Visit 6/Phase II Study Termination Visit - 24 Weeks Baseline Visits 1 , 3 , 4 , 6 last 2 Â½ hour visit 2 5 30 minute . The 'check ' phone call last approximately 5-10 minute . After 24 week , study participation .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>1 . Participants must experience symptom mild cognitive impairment ; determine study personnel . 2 . Participants must sable medication regimen 2 month prior start study ( necessary dose adjustment study acceptable ) . 3 . Participants capable give informed consent support meet Parkinson 's disease Dementia criterion ; determine study personnel . 1 . Active suicide ideation . 2 . Weighing less 100 lb ( 45 kg ) . 3 . History Deep Brain Stimulation surgery . 4 . Diagnosis Dementia 5 . Taking certain type medication may exclusion criterion , review potential participant . 6 . Females pregnant , plan become pregnant , breastfeed include study . Females childbearing potential need verify pregnant negative urine pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Cognition</keyword>
	<keyword>Memory</keyword>
	<keyword>Attention</keyword>
	<keyword>Exelon</keyword>
	<keyword>Rivastigmine</keyword>
</DOC>